Key clinical point: A novel oral Bruton’s tyrosine kinase inhibitor showed good efficacy with a favorable safety profile in pemphigus.
Major finding: Sixty percent of pemphigus patients achieved control of disease activity after 4 weeks on rilzabrutinib, an investigational oral reversible Bruton’s tyrosine kinase inhibitor.
Study details: This was a phase 2b, 24-week, open-label trial in 15 patients with pemphigus.
Disclosures: The presenter reported serving as a consultant to Principia Biopharma, sponsor of the BELIEVE-PV trial, and has received institutional research grants from numerous pharmaceutical companies.
FROM AAD 20